Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail — BioSpace coverage of biopharma industry developments.
Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare neuromuscular and central nervous system diseases.
Company Info
Sector:Biopharmaceutical
Headquarters:Cambridge, Massachusetts, United States
Founded:1980
Website:www.sarepta.com/
Upcoming Milestones & Key Dates
2027-Q1
Clinical
Elevidys label expansion data
Clinical Development Pipeline
Elevidys
Target: Micro-dystrophinSRP-9001
Target: Gene therapySRP-5051
Target: Exon 51 skippingRecent News
Leadership Team
Doug Ingram
President and Chief Executive Officer
Louise Rodino-Klapac
Chief Scientific Officer
Ian Estepan
Chief Financial Officer
Careers & Job Openings